1 Glorious Growth Stock Down 84% to Buy on the Dip in June

DOCU is transitioning from a post-pandemic normalization story to an AI monetization story, but the market is still pricing it like a low-growth legacy SaaS name. The important second-order effect is not just revenue acceleration; it is mix shift toward workflow software with deeper embedding, which should improve retention, raise switching costs, and make renewal cycles less cyclical than pure e-signature demand.

The near-term setup is favorable because management is prioritizing margin discipline while IAM is still early in penetration. That creates a cleaner earnings path over the next 2-4 quarters: even mid-single-digit top-line growth can translate into outsized EPS leverage if sales efficiency stays tight. The key risk is that AI features become table stakes faster than investors expect, limiting willingness to pay and making IAM a feature bundle rather than a standalone platform.

Consensus likely underestimates how long enterprise workflow transformations take. If IAM is gaining share of ARR from a low base, the main catalyst is not a single quarter beat but a sustained sequence of larger deployments over 12-18 months; conversely, one or two large pilots failing to expand would quickly deflate the AI narrative. The stock looks inexpensive versus its own history, but the right question is whether the multiple re-rates on ARR mix improvement or stalls until growth re-accelerates materially.